Damon A Bell1, Andrew B Kirke2, Rita Barbour2, Lynda Southwell3, Jing Pang4, Sally Burrows5, Gerald F Watts6. 1. School of Medicine & Pharmacology, University of Western Australia, Perth, Australia; Cardiometabolic Service, Department of Internal Medicine, Royal Perth Hospital, Perth, Australia; Familial Hypercholesterolaemia Western Australia (FHWA), Royal Perth Hospital, Perth, Australia; Department of Clinical Biochemistry, PathWest Royal Perth Hospital, Perth, Australia. Electronic address: damon.bell@health.wa.gov.au. 2. School of Primary, Aboriginal and Rural Health Care, University of Western Australia, Perth, Australia. 3. Familial Hypercholesterolaemia Western Australia (FHWA), Royal Perth Hospital, Perth, Australia. 4. School of Medicine & Pharmacology, University of Western Australia, Perth, Australia; Familial Hypercholesterolaemia Western Australia (FHWA), Royal Perth Hospital, Perth, Australia. 5. School of Medicine & Pharmacology, University of Western Australia, Perth, Australia. 6. School of Medicine & Pharmacology, University of Western Australia, Perth, Australia; Cardiometabolic Service, Department of Internal Medicine, Royal Perth Hospital, Perth, Australia; Familial Hypercholesterolaemia Western Australia (FHWA), Royal Perth Hospital, Perth, Australia.
Abstract
OBJECTIVE: Familial Hypercholesterolaemia (FH) is the most prevalent monogenic condition causing premature coronary artery disease, although the majority of individuals remain undiagnosed. We sought to investigate whether individuals with FH could be accurately identified in primary care. METHODS: The Dutch Lipid Clinic Network Criteria scores (DLCNCS) assessed by general practitioners (GPs) were compared with DLCNCS assessed by specialists using primary care data in 153 individuals. Thirty individuals with DLCNCS ≥4 underwent specialist review and genetic testing. Clinical FH was defined as DLCNCS ≥6, encompassing the probable and definite FH categories. RESULTS: GPs correctly classified 39 (86.7%) individuals with 'clinical FH', and 32 (94%) with 'unlikely FH' relative to specialists. Lin's concordance correlation coefficient was high (0.832 (0.783 - 0.881), p< 0.001) between specialist and GPs, with an overall agreement of 83.6%, κ 0.744 (0.642 - 0.831). After specialist review, 15 individuals (50%) were diagnosed with clinical FH, four (26.7%) had FH mutations. GPs correctly classified 12 (80%) of these individuals with clinical FH. CONCLUSION: GPs can accurately identify individuals at high and low risk of FH using the DLCNCS, which may augment opportunistic FH detection in the community. Increased education may enhance the diagnostic accuracy of FH in primary care.
OBJECTIVE:Familial Hypercholesterolaemia (FH) is the most prevalent monogenic condition causing premature coronary artery disease, although the majority of individuals remain undiagnosed. We sought to investigate whether individuals with FH could be accurately identified in primary care. METHODS: The Dutch Lipid Clinic Network Criteria scores (DLCNCS) assessed by general practitioners (GPs) were compared with DLCNCS assessed by specialists using primary care data in 153 individuals. Thirty individuals with DLCNCS ≥4 underwent specialist review and genetic testing. Clinical FH was defined as DLCNCS ≥6, encompassing the probable and definite FH categories. RESULTS: GPs correctly classified 39 (86.7%) individuals with 'clinical FH', and 32 (94%) with 'unlikely FH' relative to specialists. Lin's concordance correlation coefficient was high (0.832 (0.783 - 0.881), p< 0.001) between specialist and GPs, with an overall agreement of 83.6%, κ 0.744 (0.642 - 0.831). After specialist review, 15 individuals (50%) were diagnosed with clinical FH, four (26.7%) had FH mutations. GPs correctly classified 12 (80%) of these individuals with clinical FH. CONCLUSION: GPs can accurately identify individuals at high and low risk of FH using the DLCNCS, which may augment opportunistic FH detection in the community. Increased education may enhance the diagnostic accuracy of FH in primary care.
Authors: Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska Journal: Arch Med Sci Date: 2021-11-08 Impact factor: 3.318
Authors: Luisa Silva; Laura Condon; Nadeem Qureshi; Brittany Dutton; Stephen Weng; Joe Kai Journal: Br J Gen Pract Date: 2022-06-30 Impact factor: 6.302
Authors: Nadeem Qureshi; Maria Luisa R Da Silva; Hasidah Abdul-Hamid; Stephen F Weng; Joe Kai; Jo Leonardi-Bee Journal: Cochrane Database Syst Rev Date: 2021-10-07
Authors: Tom Brett; Dick C Chan; Jan Radford; Clare Heal; Gerard Gill; Charlotte Hespe; Cristian Vargas-Garcia; Carmen Condon; Barbara Sheil; Ian W Li; David R Sullivan; Alistair W Vickery; Jing Pang; Diane E Arnold-Reed; Gerald F Watts Journal: Heart Date: 2021-05-20 Impact factor: 5.994
Authors: Paul Crosland; Ross Maconachie; Sara Buckner; Hugh McGuire; Steve E Humphries; Nadeem Qureshi Journal: Atherosclerosis Date: 2018-05-17 Impact factor: 5.162